JP2011225600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011225600A5 JP2011225600A5 JP2011156813A JP2011156813A JP2011225600A5 JP 2011225600 A5 JP2011225600 A5 JP 2011225600A5 JP 2011156813 A JP2011156813 A JP 2011156813A JP 2011156813 A JP2011156813 A JP 2011156813A JP 2011225600 A5 JP2011225600 A5 JP 2011225600A5
- Authority
- JP
- Japan
- Prior art keywords
- naltrexone
- long acting
- polymer
- solution
- acting formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 20
- 229960003086 naltrexone Drugs 0.000 claims 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 12
- 238000009472 formulation Methods 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 229920000642 polymer Polymers 0.000 claims 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 5
- 239000000839 emulsion Substances 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 4
- 235000019445 benzyl alcohol Nutrition 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000000605 extraction Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000012071 phase Substances 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 239000010419 fine particle Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- DQCKKXVULJGBQN-UWFFTQNDSA-N (4r,4as,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound C([C@@]12[C@@]3(O)CCC(=O)C1OC=1C(O)=CC=C(C2=1)C[C@]31[H])CN1CC1CC1 DQCKKXVULJGBQN-UWFFTQNDSA-N 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000012074 organic phase Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 229940065514 poly(lactide) Drugs 0.000 claims 1
- 238000000638 solvent extraction Methods 0.000 claims 1
- 230000003068 static effect Effects 0.000 claims 1
- 238000001291 vacuum drying Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56454204P | 2004-04-22 | 2004-04-22 | |
| US60/564,542 | 2004-04-22 | ||
| US11/083,167 US7919499B2 (en) | 2004-04-22 | 2005-03-17 | Naltrexone long acting formulations and methods of use |
| US11/083,167 | 2005-03-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007509472A Division JP5426094B2 (ja) | 2004-04-22 | 2005-03-18 | ナルトレキソン長時間作用性製剤および使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011225600A JP2011225600A (ja) | 2011-11-10 |
| JP2011225600A5 true JP2011225600A5 (enExample) | 2013-03-28 |
Family
ID=35187918
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007509472A Expired - Fee Related JP5426094B2 (ja) | 2004-04-22 | 2005-03-18 | ナルトレキソン長時間作用性製剤および使用方法 |
| JP2011156813A Pending JP2011225600A (ja) | 2004-04-22 | 2011-07-15 | ナルトレキソン長時間作用性製剤および使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007509472A Expired - Fee Related JP5426094B2 (ja) | 2004-04-22 | 2005-03-18 | ナルトレキソン長時間作用性製剤および使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US7919499B2 (enExample) |
| EP (2) | EP2386269A3 (enExample) |
| JP (2) | JP5426094B2 (enExample) |
| KR (2) | KR20070005722A (enExample) |
| CN (1) | CN103251597A (enExample) |
| AU (1) | AU2005239989B2 (enExample) |
| CA (1) | CA2563086C (enExample) |
| NZ (1) | NZ549976A (enExample) |
| RU (1) | RU2370257C2 (enExample) |
| WO (1) | WO2005107753A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2818973B2 (ja) | 1990-10-22 | 1998-10-30 | 株式会社藤井鉄工所 | スキップ式水路用スクリーン除塵機 |
| US20100196436A1 (en) * | 2009-01-30 | 2010-08-05 | Gooberman Lance L | Implants containing disulfiram and an anti-inflammatory agent |
| US8791093B2 (en) * | 2009-05-29 | 2014-07-29 | Lance L. Gooberman | Pharmaceutical delivery systems for treatment of substance abuse and other addictions |
| RU2471478C1 (ru) * | 2011-12-08 | 2013-01-10 | Станислав Анатольевич Кедик | Фармацевтическая композиция для лечения алкоголизма, наркомании и токсикомании с улучшенным профилем высвобождения налтрексона |
| US20160279124A1 (en) * | 2015-03-27 | 2016-09-29 | Dan Markel | Method for Treating Addiction |
| CN113164395A (zh) | 2018-10-15 | 2021-07-23 | 株式会社钟根堂 | 注射用长效纳屈酮微粒组合物 |
| WO2020135576A1 (en) * | 2018-12-27 | 2020-07-02 | Alar Pharmaceuticals Inc. | Naltrexone injectable sustained release formulation |
| GR1009871B (el) * | 2019-07-30 | 2020-11-12 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει μικροσφαιριδια ναλτρεξονης και μεθοδος παρασκευης αυτου |
| US11752143B2 (en) | 2020-12-31 | 2023-09-12 | Soin Therapeutics Llc | Methods of using low dose naltrexone to treat chronic pain |
| US12343340B2 (en) | 2020-12-31 | 2025-07-01 | Soin Therapeutics Llc | Methods of using low dose naltrexone to treat chronic pain |
| US11197819B1 (en) | 2021-04-09 | 2021-12-14 | Drug Delivery Company, Llc | Extended release bioabsorbable subcutaneous medicinal dosage delivery implant system |
| AU2022202053A1 (en) | 2021-09-17 | 2023-04-06 | Biocorrx, Inc. | Biodegradable implant including naltrexone |
| WO2023114557A2 (en) * | 2021-12-17 | 2023-06-22 | Journey Colab Corp. | METHODS OF TREATING SUBSTANCE USE DISORDERS USING 5-MeO-DMT |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4719219A (en) * | 1982-03-30 | 1988-01-12 | Per A. E. Carlsson | Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders |
| US4882335A (en) * | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
| ES2084698T5 (es) * | 1989-05-04 | 2005-03-01 | Southern Research Institute | Procedimiento de encapsulacion. |
| US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
| EP2275089A1 (en) * | 1993-11-19 | 2011-01-19 | Alkermes Controlled Therapeutics, Inc. | Preparation of biodegradable microparticles containing a biologically active agent |
| US5922253A (en) * | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
| CA2220768A1 (en) * | 1996-03-13 | 1997-09-18 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
| US5792477A (en) * | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
| US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6306425B1 (en) * | 1999-04-09 | 2001-10-23 | Southern Research Institute | Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol |
| JP4913298B2 (ja) | 1999-08-27 | 2012-04-11 | ブルックウッド ファーマシューティカルズ，インコーポレイティド | 注射可能なブプレノルフィン微粒子組成物及びその使用 |
| EP1237544A1 (en) * | 1999-12-16 | 2002-09-11 | Trident Technologies, LLC | System and method for extended delivery of a therapeutic agent with its receptor loading dose |
| US6264987B1 (en) * | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| NZ540318A (en) | 2002-10-31 | 2007-09-28 | Umd Inc | Therapeutic compositions for drug delivery to and through covering epithelia |
| CN1166360C (zh) * | 2002-11-07 | 2004-09-15 | 上海医药工业研究院 | 一种纳曲酮长效注射微球组合物及制备方法和应用 |
| WO2004064752A2 (en) | 2003-01-22 | 2004-08-05 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| US7279579B2 (en) | 2003-06-04 | 2007-10-09 | Alkermes, Inc. | Polymorphic forms of naltrexone |
-
2005
- 2005-03-17 US US11/083,167 patent/US7919499B2/en active Active
- 2005-03-18 CN CN2013101596188A patent/CN103251597A/zh active Pending
- 2005-03-18 KR KR1020067023387A patent/KR20070005722A/ko not_active Ceased
- 2005-03-18 EP EP11161854A patent/EP2386269A3/en not_active Withdrawn
- 2005-03-18 KR KR1020097009360A patent/KR20090050111A/ko not_active Ceased
- 2005-03-18 RU RU2006137349/14A patent/RU2370257C2/ru active
- 2005-03-18 EP EP05728952A patent/EP1740120A4/en not_active Ceased
- 2005-03-18 NZ NZ549976A patent/NZ549976A/en not_active IP Right Cessation
- 2005-03-18 AU AU2005239989A patent/AU2005239989B2/en not_active Expired
- 2005-03-18 CA CA2563086A patent/CA2563086C/en not_active Expired - Lifetime
- 2005-03-18 WO PCT/US2005/009133 patent/WO2005107753A2/en not_active Ceased
- 2005-03-18 JP JP2007509472A patent/JP5426094B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-01 US US13/037,713 patent/US20110212985A1/en not_active Abandoned
- 2011-07-15 JP JP2011156813A patent/JP2011225600A/ja active Pending
-
2013
- 2013-04-26 US US13/871,534 patent/US20140155424A1/en not_active Abandoned
-
2017
- 2017-04-13 US US15/486,869 patent/US20180064814A1/en not_active Abandoned
-
2021
- 2021-04-29 US US17/244,110 patent/US20210244818A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011225600A5 (enExample) | ||
| Tuleu et al. | Comparative bioavailability study in dogs of a self‐emulsifying formulation of progesterone presented in a pellet and liquid form compared with an aqueous suspension of progesterone | |
| JP6072121B2 (ja) | リスペリドン徐放性ミクロスフェア組成物 | |
| Kalepu et al. | Insoluble drug delivery strategies: review of recent advances and business prospects | |
| JP7038741B2 (ja) | 放出制御が容易な徐放性薬物微粒子の製造方法 | |
| Kim et al. | Fabrication and evaluation of valsartan–polymer–surfactant composite nanoparticles by using the supercritical antisolvent process | |
| JP2015044823A5 (enExample) | ||
| JP2016513721A5 (enExample) | ||
| CA2893959A1 (en) | Pharmaceutical compositions | |
| He et al. | Preparation and in vitro–in vivo evaluation of teniposide nanosuspensions | |
| JP2017536401A5 (enExample) | ||
| WO2011022861A1 (zh) | 氟维司群纳米球/微球及其制备方法和用途 | |
| CN102188384A (zh) | 调控利培酮微球释放行为和控制微球尺寸大小的制备微球方法 | |
| JP2014525449A5 (enExample) | ||
| D’Souza et al. | Microsphere delivery of Risperidone as an alternative to combination therapy | |
| CN102579362B (zh) | 一种非洛地平缓释微球及其制备方法 | |
| AU2015323321A1 (en) | Long acting pharmaceutical compositions | |
| CN106474070B (zh) | 一种克服停滞期、恒速释放疏水性药物的微球及制备方法 | |
| CN103893129B (zh) | 帕潘立酮缓释微球及其注射剂和该缓释微球的制备方法 | |
| CN103169662A (zh) | 一种紫杉醇高分子纳米颗粒及制备方法 | |
| WO2013060304A1 (zh) | 紫杉醇或其同系物的固体分散体及其制备方法 | |
| CN116459220A (zh) | 昔萘酸普拉克索缓释微球及其制备方法与应用 | |
| Devireddy et al. | Solubility and bioavailability improvement of gliclazide by solid dispersions using novel carriers | |
| CN104523605A (zh) | 一种曲普瑞林微球及其制备方法与应用 | |
| CN104434797A (zh) | 一种氟苯尼考固体自乳化制剂 |